NCT00006269View on ClinicalTrials.gov

Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

PHASE3TerminatedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

December 31, 1999

Primary Completion Date

December 31, 1999

Conditions
Colorectal CancerDiarrhea
Interventions
DRUG

irinotecan hydrochloride

DRUG

octreotide acetate

Trial Locations (2)

07936

Novartis Pharmaceuticals Corporation, East Hanover

08543

Theradex, Princeton

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY